Company & Sponsor Intelligence

University Hospital Tuebingen

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials10

Recruiting1

Completed5

Countries2

Therapeutic footprint

adhddementia_otherdepressionneuromuscularother_neurologyother_psychiatryparkinsons

Indexed studies

NCT03039387Effects of tDCS on Cognitive Control and Emotion Regulation in Depressed Patients
depression · GermanyNA

NCT03236454tDCS-enhanced Working Memory Training in Subjective Cognitive Decline
dementia_other · GermanyNA

NCT05479032Amantadine for Neuroenhancement in Acute Patients Study
other_psychiatry · GermanyPHASE2

NCT07055087Prevent Cognitive Decline in GBA-associated Parkinson's Disease
parkinsons · FrancePHASE2

NCT00518024Safety and Effectiveness of Repetitive Transcranial Magnetic Stimulation in the Treatment of Tinnitus
other_neurology · GermanyPHASE2

NCT02572180A Biofeedback Training in Schoolchildren With an Attention-Deficit/Hyperactivity Disorder (ADHD)
adhd · GermanyNA

NCT04367350Prospective Registry of Corona Virus Disease 2019 (Covid-19) Patients With Neuromuscular Involvement
neuromuscular · GermanyUNKNOWN

NCT03104088Studying Cognition in SPG4
dementia_other · GermanyCOMPLETED

NCT02375308Efficacy of Cognitive Behavioral to Hypnotherapeutic Treatment of Depression
depression · GermanyNA

NCT01355835Combined STN/SNr-DBS for the Treatment of Refractory Gait Disorders in Parkinson's Disease
parkinsons · GermanyPHASE2

Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →